Body Mass Index As A Prognostic Factor In HER-2 Positive Early Breast Cancer Patients And Its Effect On Duration Of Treatment With Trastuzumab: A Retrospective Study.

ABSTRACT

Objectives: To evaluate prognostic value of body mass index in human epidermal growth factor receptor 2-positive early breast cancer, and to evaluate the duration of trastuzumab administration. Method: The retrospective study was conducted from March 2020 to December 2021 at Kafrelsheikh University Hospital and Zagazig University Hospital, Egypt, and comprised data of women diagnosed between 2015 and 2017 with stage III human epidermal growth factor receptor 2-positivebreast cancer, who were treated with adjuvant chemotherapy and trastuzumab for a year. Body massindex had been calculated at the time of diagnosis, and data was divided into 3 groups average weight group A, overweight group B and obese group C. Disease-free survival, distant disease-free survival and overall survival were estimated for all the three groups. Data was analysed using SPSS 26. RESULTS: The mean age of 160 cases was 44.99±11.35 years(range 25-66 years). There were 93(58.1) postmenopausal women, 60(37.5%) had positive family history and 128 (80%) underwent modified radical mastectomy. There were 60(37.5%) patients in group A, 49(30.6%) in group B and 51(31.9%) in group C. There was significant association of body mass index with disease-free survival and distant disease-free survival (p<0.05), but not with overall survival (p>0.05). Significant difference was noted between body mass index and duration of trastuzumab (p<0.001). CONCLUSIONS: Body massindex wasfound to be an independent prognostic factor for human epidermal growth factor receptor 2-positiveearly breast cancer.